ID   L-1236
AC   CVCL_2096
AS   CVCL_5155
SY   L1236; L 1236
DR   CLO; CLO_0037179
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473524
DR   BioSample; SAMN10987806
DR   cancercelllines; CVCL_2096
DR   Cell_Model_Passport; SIDM00313
DR   Cosmic; 988702
DR   Cosmic; 1013908
DR   Cosmic; 1289701
DR   Cosmic; 1432037
DR   Cosmic; 2276328
DR   Cosmic; 2464306
DR   Cosmic-CLP; 1330935
DR   DepMap; ACH-000702
DR   DSMZ; ACC-530
DR   DSMZCellDive; ACC-530
DR   EGA; EGAS00001000978
DR   GDSC; 1330935
DR   GEO; GSM381297
DR   GEO; GSM499722
DR   GEO; GSM499730
DR   GEO; GSM552449
DR   GEO; GSM646531
DR   GEO; GSM646536
DR   GEO; GSM887257
DR   GEO; GSM888332
DR   GEO; GSM1670027
DR   IARC_TP53; 23617
DR   IGRhCellID; L1236
DR   LiGeA; CCLE_723
DR   LINCS_LDP; LCL-2010
DR   Lonza; 25
DR   PharmacoDB; L1236_813_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2096
DR   Wikidata; Q54900859
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8605360;
RX   PubMed=12865944;
RX   PubMed=17065008;
RX   PubMed=19380639;
RX   PubMed=20628145;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~48 hours (DSMZ=ACC-530).
CC   HLA typing: A*02:01,02:01; B*51:01,51:01; C*02:02,02:02 (PubMed=26589293).
CC   HLA typing: A*02:01:01,02:01:01; B*51:01:01,51:01:01; C*02:02:02,02:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,05:03:01; DRA*01:01:01,01:01:01; DRB1*14:54:01,14:54:01 (DSMZCellDive=ACC-530).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639).
CC   Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Simple; p.Trp142Ter (c.425G>A) (G491A); Zygosity=Heterozygous (PubMed=19380639).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Fusion of Ex9 wiith an Alu-element; Zygosity=Unspecified (PubMed=17065008).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=70.78%; European, South=27.1% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,14
ST   D13S317: 13
ST   D16S539: 9,13
ST   D18S51: 15,19
ST   D19S433: 14,17
ST   D21S11: 27
ST   D2S1338: 18
ST   D3S1358: 15,16
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 12,13
ST   FGA: 21,25
ST   Penta D: 10
ST   Penta E: 7,10
ST   TH01: 6
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8605360; DOI=10.1182/blood.V87.8.3418.bloodjournal8783418;
RA   Wolf J., Kapp U., Bohlen H., Kornacker M., Schoch C., Stahl B.,
RA   Mucke S., von Kalle C., Fonatsch C., Schaefer H.-E., Hansmann M.-L.,
RA   Diehl V.;
RT   "Peripheral blood mononuclear cells of a patient with advanced
RT   Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed
RT   Sternberg cells.";
RL   Blood 87:3418-3428(1996).
//
RX   PubMed=12865944;
RA   Schwering I., Brauninger A., Distler V., Jesdinsky J., Diehl V.,
RA   Hansmann M.-L., Rajewsky K., Kuppers R.;
RT   "Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B
RT   cells: identification of Hodgkin's lymphoma-specific genes.";
RL   Mol. Med. 9:85-95(2003).
//
RX   PubMed=17065008; DOI=10.1080/10428190600667721;
RA   Feuerborn A., Moritz C., von Bonin F., Dobbelstein M., Trumper L.,
RA   Sturzenhofecker B., Kube D.;
RT   "Dysfunctional p53 deletion mutants in cell lines derived from
RT   Hodgkin's lymphoma.";
RL   Leuk. Lymphoma 47:1932-1940(2006).
//
RX   PubMed=19380639; DOI=10.1084/jem.20090528;
RA   Schmitz R., Hansmann M.-L., Bohle V., Martin-Subero J.I., Hartmann S.,
RA   Mechtersheimer G., Klapper W., Vater I., Giefing M., Gesk S.,
RA   Stanelle J., Siebert R., Kuppers R.;
RT   "TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and
RT   primary mediastinal B cell lymphoma.";
RL   J. Exp. Med. 206:981-989(2009).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//